Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 7Phase 3 3Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Classical hematology 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 10Zoledronic Acid 8ixazomib 4daratumumab 4Thalidomide 4Melphalan 4Cyclophosphamide 4tocilizumab 3Prednisone 3pomalidomide 2carfilzomib 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1fludarabine phosphate 1fludarabine 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Injections × Plasma cell × Clear all
NCT06425276 2024-05-23

Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation

CASI Pharmaceuticals (China) Co., Ltd.

Phase 4 Completed
67 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡